한국융합학회논문지 (Journal of the Korea Convergence Society)

  • 제13권1호
  • /
  • Pages.101-107
  • /
  • 2022
  • /
  • 2233-4890(pISSN)
  • /
  • 2713-6353(eISSN)
한국융합학회 (Korea Convergence Society)
권호 표지
DOI QR코드

DOI QR Code

[논문철회]항암백신 tertomotide의 항염활성 연구

[Retraction]Anti-inflammatory activity of a short peptide designed for anti-cancer: a beneficial off-target effect of tertomotide

  • 이효성 (서원대학교 제약식품공학부)
  • Lee, Hyosung (Department of Food & Pharmaceutical Science & Engineering, Seowon University)
  • 투고 : 2021.12.05
  • 심사 : 2022.01.20
  • 발행 : 2022.01.28
PDF 다운로드
⟨ 이전 논문 다음 논문 ⟩

초록

Tertomotide는 항암제로 개발된 펩타이드 백신이다. 그러나 동물실험과 임상시험에서 염증성 증상이 완화되는 현상이 발견된바 있다. 이에 tertomotide가 항염물질로 작용하는지 확인하기 위하여 직접적인 항염활성과 그 작용기전을 조사하였다. 이를 위해 LPS 또는 PMA에 의해 활성화된 monocyte에 tertomotide를 처리한 후 염증성 cytokine 생산과 관련된 신호전달과정을 관찰하였다. Monocyte에서 tertomotide는 TNF-α, IL-1β, IL-8 등 염증성 싸이토카인의 생산을 감소시켰고 NF-κB 신호를 감쇄시켰으며 또한 TNF-α에 의한 ERK1/2와 P38 MAPK의 활성화를 저해하였다. 이 결과는 tertomotide 처치에 따른 염증성 질환 완화가 NF-κB/STAT3의 신호의 감쇄와 항염활성에 의한 것이라고 설명할 수 있고 이를 활용하여 신규 항염 약물의 도출이 가능할 것으로 판단된다. 이는 면역학적 활성을 목표로 계산화학적으로 설계된 물질의 생물학적 성질을 활용하여 새로운 약물을 도출하는 융합연구의 예시가 될 것이다.

Tertomotide is a peptide vaccine developed for anti-cancer therapy. Since it has been found to ameliorate inflammatory symptoms in animal studies and clinical test, we investigated anti-inflammation activity of the tertomotide and the mechanism of action in monocyte in order to assess if tertomotide may serve as an anti-inflammatory agent by checking inflammatory cytokines and related signaling pathway following tertomotide treatment. We found that tertomotide reduced the level of pro-inflammatory cytokines such as TNF-α, IL-1β, IL-8 in LPS- or PMA-stimulated monocyte cell line and suppressed NF-κB signaling including the activation of ERK1/2 and P38 MAPK following TNF-α treatment. These results may correlate to the beneficial findings in animal studies, implicating that tertomotide may act as a potential anti-inflammatory agent. This study is an exemplary case for convergence that a computationally designed peptide for immunological purpose exerting unexpected biological activity may elicit novel anti-inflammatory drug.

키워드

참고문헌

  1. N. Relitti et al. (2020). Telomerase-based cancer therapeutics: A review on their clinical trials. Current Topics in Medicinal Chemistry, 20(6), 433-457. https://doi.org/10.2174/1568026620666200102104930
  2. Y. H. Park et al. (2019). GV1001 inhibits cell viability and induces apoptosis in castration-resistant prostate cancer cells through the AKT/NF-kappaB/VEGF pathway. Journal of Cancer. 10(25), 6269-6277. https://doi.org/10.7150/jca.34859
  3. V. E. Shaw et al. (2010). Current status of GV1001 and other telomerase vaccination strategies in the treatment of cancer. Expert Review of Vaccines, 9(9), 1007-16. https://doi.org/10.1586/erv.10.92
  4. J. Choi et al. (2015). The anti-inflammatory effect of GV1001 mediated by the down regulation of ENO1-induced pro-inflammatory cytokine production. Immune Network, 15(6), 291-303. https://doi.org/10.4110/in.2015.15.6.291
  5. Y. J. Ko et al. (2015). The anti-inflammatory effect of human telomerase-derived peptide on P. gingivalis lipopolysaccharide-induced inflammatory cytokine production and its mechanism in human dental pulp cells. Mediators of Inflammation, 2015(385127), 1-8.
  6. T. Y. Koo et al. (2014). Protective effect of peptide GV1001 against renal ischemia-reperfusion injury in mice. Transplant Proceedings. 46(4), 1117-22. https://doi.org/10.1016/j.transproceed.2013.12.019
  7. E. K. Lee et al. (2020). A telomerase-derived peptide vaccine inhibits laser-induced choroidal neovascularization in a rat model. Translational Research. 216, 30-42. https://doi.org/10.1016/j.trsl.2019.10.001
  8. Y. M. Choi et al. (2020). A telomerase-derived peptide exerts an anti-hepatitis B virus effect via mitochondrial DNA stress-dependent type I interferon production. Frontiers in Immunology. 11(652), DOI : 10.3389/fimmu.2020.00652
  9. J. Auwerx et al. (1991). The human leukemia cell line, THP-1: a multifacetted model for the study of monocyte-macrophage differentiation. Experientia, 47(1), 22-31. https://doi.org/10.1007/BF02041244
  10. Y. Zhang et al. (2019). Therapeutic approaches in mitochondrial dysfunction, inflammation, and autophagy in uremic cachexia: role of aerobic exercise. Mediators in Inflammations, 2019(2879014), 1-11.
  11. C. Madeddu, A. Maccio & G. Mantovani. (2012). Multitargeted treatment of cancer cachexia. Critical Reviews in Oncogenesis, 17(3), 305-14. https://doi.org/10.1615/CritRevOncog.v17.i3.80
  12. C. Staff et al. (2014). Telomerase (GV1001) vaccination together with gemcitabine in advanced pancreatic cancer patients. International Journal of Oncology, 45(3), 1293-303. https://doi.org/10.3892/ijo.2014.2496
  13. W. Chanput, J. J. Mes & H. J. Wichers. (2014). THP-1 cell line: an in vitro cell model for immune modulation approach. International Immuno pharmacology, 23(1), 37-45. https://doi.org/10.1016/j.intimp.2014.08.002
  14. N. E. Annels et al. (2014). The effects of gemcitabine and capecitabine combination chemotherapy and of low-dose adjuvant GM-CSF on the levels of myeloid-derived suppressor cells in patients with advanced pancreatic cancer. Cancer Immunololgy and Immunotherapy, 63(2), 175-83. https://doi.org/10.1007/s00262-013-1502-y
  15. C. C. Hsu et al. (2013). Yuwen02f1 suppresses LPS-induced endotoxemia and adjuvant-induced arthritis primarily through blockade of ROS formation, NF-κB and MAPK activation. Biochemical Pharmacology. 85(3), 385-95. https://doi.org/10.1016/j.bcp.2012.11.002
  16. K. L. Zapadka. (2017). Factors affecting the physical stability (aggregation) of peptide therapeutics. Interface focus. 7(6), 20170030. https://doi.org/10.1098/rsfs.2017.0030